FAI December 2020: Effect of Metformin on Development of Tendinopathy Due to Mechanical Overloading in an Animal Model

<p>Tendinopathy is a debilitating tendon disorder that affects millions of Americans and costs billions of health care dollars every year. High mobility group box 1 (HMGB1), a known tissue damage signaling molecule, has been identified as a mediator in the development of tendinopathy due to mechanical overloading of tendons in mice. Metformin (Met), a drug approved by the Food and Drug Administration used for the treatment of type 2 diabetes, specifically inhibits HMGB1. This study tested the hypothesis that Met would prevent mechanical overloading-induced tendinopathy in a mouse model of tendinopathy created by intensive treadmill running (ITR).</p> <p>In conclusion, inhibition of HMGB1 by injections of Met prevented tendinopathy development due to mechanical overloading in the Achilles tendon in mice.</p> <p> </p> <p>To view the article click <a href= "https://journals.sagepub.com/doi/full/10.1177/1071100720966318"><strong>here.</strong></a></p>